- Home
- UNCY vs CNTB Comparison
UNCY vs CNTB Comparison
Compare UNCY & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UNCY | CNTB |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.1M | 140.4M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | UNCY | CNTB |
|---|---|---|
| Price | $4.81 | $1.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $25.67 | $8.67 |
| AVG Volume (30 Days) | 743.2K | ★ 1.6M |
| Earning Date | 05-13-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $675,000.00 | $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $582.86 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.72 | $1.06 |
| 52 Week High | $8.74 | $3.82 |
Technical Indicators
Market Signals| Indicator | UNCY | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 38.41 | 32.54 |
| Support Level | $3.93 | N/A |
| Resistance Level | $5.86 | $2.78 |
| Average True Range (ATR) | 0.22 | 0.26 |
| MACD | -0.04 | -0.11 |
| Stochastic Oscillator | 9.00 | 11.45 |
Price Performance
Historical ComparisonAbout UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.